Navigation Links
InterMune Announces Progress on Pirfenidone in IPF
Date:4/21/2008

epatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
2. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
3. InterMune Announces Start of Phase 1b Trial of ITMN-191
4. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... YORK , Sept. 16, 2014  This report analyzes ... Units, The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Devices, and Medication. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:9/16/2014)... 16, 2014 Adaptive Biotechnologies, a clinical stage ... profile the adaptive immune system, is pleased to announce ... Commercial Officer (CCO). The addition of Brain to the ... from leading global healthcare companies, including Dean Schorno ... from Genomic Health and Sean Nolan (CTO) ...
Breaking Medicine Technology:Global Digital Radiography Industry 2Global Digital Radiography Industry 3Global Digital Radiography Industry 4Global Digital Radiography Industry 5Global Digital Radiography Industry 6Global Digital Radiography Industry 7Global Digital Radiography Industry 8Global Digital Radiography Industry 9Global Digital Radiography Industry 10Global Digital Radiography Industry 11Global Digital Radiography Industry 12Global Digital Radiography Industry 13Global Digital Radiography Industry 14Global Digital Radiography Industry 15Global Digital Radiography Industry 16Global Digital Radiography Industry 17Global Digital Radiography Industry 18Global Digital Radiography Industry 19Global Digital Radiography Industry 20Global Digital Radiography Industry 21Global Digital Radiography Industry 22Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13Global Foot Care Products Industry 14Global Foot Care Products Industry 15
... Oncology, Inc. formerly Champions Biotechnology, Inc. (OTC: CSBR) reported ... First Quarter Financial Results:Total operating revenues for the first ... $1.60 million in the first quarter of fiscal 2011. ... 2012 were $3.85 million compared to $2.20 million in ...
... SAN DIEGO, Sept. 13, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ...   The live presentation takes place on ... 6:00 a.m. Pacific Time.  The presentation will be webcast and ...
Cached Medicine Technology:Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 2Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 3Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 4Champions Oncology Reports Fiscal 2012 First Quarter Financial Results 5
(Date:9/16/2014)... DC September 14, 2014 A ... everolimus-eluting stents (EES) and drug-eluting balloons (DEB) ... stents found that EES provided superior late ... , Findings were reported today at ... scientific symposium. Sponsored by the Cardiovascular Research ...
(Date:9/16/2014)... that corn absorbs the right balance of nitrogen, phosphorus ... Purdue and Kansas State University study finds. , A ... the U.S. and other regions showed that high yields ... took up key nutrients at specific ratios - nitrogen ... and potassium at a ratio of 1-to-1. These nutrient ...
(Date:9/16/2014)... September 16, 2014 This year’s theme ... and Sustainable company Glen Mills, Pennsylvania, September 15, 2014- ... one of the fastest growing companies in the country, ... flower, shrub, and tree health-care by naturally decreasing disease ... development. Today it announced that it will hold its ...
(Date:9/16/2014)... Los Angeles, CA (PRWEB) September 16, 2014 ... the League of United Latin American Citizens (LULAC) will ... California. LULAC’s Feria de Salud will feature free health ... Other free testing includes glucose and cholesterol levels ... screenings will be available for children under 6 years ...
(Date:9/16/2014)... Almost all the various treatment options for blood ... and effective, new research shows. In exploring ... blood clots as deep vein thrombosis or pulmonary ... analyzed outcomes associated with eight blood-thinning options, including ... combination with vitamin K antagonists. The ...
Breaking Medicine News(10 mins):Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News: Most Treatments for Blood Clots Appear Safe, Effective 2
... THURSDAY, June 9 (HealthDay News) -- Children are among those ... ocular toxocariasis (OT), which can lead to permanent vision loss, ... can occur when a person ingests dirt that,s contaminated with ... dog or cat. Larvae that emerge from the eggs migrate ...
... Should physicians be banned from assisting in a ... so? A recent ruling by the American Board of ... capital punishment, and other medical boards may act similarly. ... concludes that decertification of physicians participating in ...
... where to eat could literally tip the scales on his ... perceptions of family meals carry more weight, so to speak, ... recently in The Journal of Nutrition Education and Behavior ... special family time certainly do not see a fast-food restaurant ...
... stomach and pancreas could be detected much sooner with a ... of Edinburgh have identified key proteins in the urine of ... detection of these cancers in people who have not yet ... enable patients to be diagnosed much earlier, leading to improved ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) ... for a label warning on the popular statin Zocor because ... in the highest doses. This risk has been seen ... day, particularly during the first year of treatment, the agency ...
... into a wallet or pursebut it could mean the difference between ... stores personal medical data (e.g. information on existing medical conditions, allergies ... enabling the data to be accessed in just a few moments. ... have been trialled in the UK. This working prototype has ...
Cached Medicine News:Health News:Tainted Soil May Put Kids at Risk for Vision Loss 2Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 2Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 3Health News:Children eschew the fat if dads aren't lenient 2Health News:Children eschew the fat if dads aren't lenient 3Health News:Simple test could hold key to early diagnosis of cancers 2Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:MyCare -- the 'card' that could save your life 2
Scoville cervical disc retractor, self-retaining with ratchet action....
... Image-Line offers superior retractor blade stability ... all cervical spine retraction objectives. The ... rapid and accurate blade size determination. ... accommodates a variety of patients and ...
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
The High Sensitivity C-Reactive Protein (RCRP) Flex reagent cartridge is an in vitro diagnostic test intended for the quantitative determination of CRP in serum and plasma. This assay is not availabl...
Medicine Products: